Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 20
Filter
1.
Sci Transl Med ; 16(748): eadk1358, 2024 May 22.
Article in English | MEDLINE | ID: mdl-38776392

ABSTRACT

Blood-CNS barrier disruption is a hallmark of numerous neurological disorders, yet whether barrier breakdown is sufficient to trigger neurodegenerative disease remains unresolved. Therapeutic strategies to mitigate barrier hyperpermeability are also limited. Dominant missense mutations of the cation channel transient receptor potential vanilloid 4 (TRPV4) cause forms of hereditary motor neuron disease. To gain insights into the cellular basis of these disorders, we generated knock-in mouse models of TRPV4 channelopathy by introducing two disease-causing mutations (R269C and R232C) into the endogenous mouse Trpv4 gene. TRPV4 mutant mice exhibited weakness, early lethality, and regional motor neuron loss. Genetic deletion of the mutant Trpv4 allele from endothelial cells (but not neurons, glia, or muscle) rescued these phenotypes. Symptomatic mutant mice exhibited focal disruptions of blood-spinal cord barrier (BSCB) integrity, associated with a gain of function of mutant TRPV4 channel activity in neural vascular endothelial cells (NVECs) and alterations of NVEC tight junction structure. Systemic administration of a TRPV4-specific antagonist abrogated channel-mediated BSCB impairments and provided a marked phenotypic rescue of symptomatic mutant mice. Together, our findings show that mutant TRPV4 channels can drive motor neuron degeneration in a non-cell autonomous manner by precipitating focal breakdown of the BSCB. Further, these data highlight the reversibility of TRPV4-mediated BSCB impairments and identify a potential therapeutic strategy for patients with TRPV4 mutations.


Subject(s)
Blood-Brain Barrier , Endothelial Cells , Gain of Function Mutation , Motor Neurons , TRPV Cation Channels , Animals , TRPV Cation Channels/metabolism , TRPV Cation Channels/genetics , Motor Neurons/pathology , Motor Neurons/metabolism , Endothelial Cells/metabolism , Endothelial Cells/pathology , Blood-Brain Barrier/metabolism , Blood-Brain Barrier/pathology , Mice , Nerve Degeneration/pathology , Nerve Degeneration/genetics , Phenotype , Spinal Cord/pathology , Spinal Cord/metabolism
2.
Hum Mol Genet ; 32(8): 1276-1288, 2023 04 06.
Article in English | MEDLINE | ID: mdl-36413117

ABSTRACT

Charcot-Marie-Tooth disease is an inherited peripheral neuropathy that is clinically and genetically heterogenous. Mutations in IGHMBP2, a ubiquitously expressed DNA/RNA helicase, have been shown to cause the infantile motor neuron disease spinal muscular atrophy with respiratory distress type 1 (SMARD1), and, more recently, juvenile-onset Charcot-Marie-Tooth disease type 2S (CMT2S). Using CRISPR-cas9 mutagenesis, we developed the first mouse models of CMT2S [p.Glu365del (E365del) and p.Tyr918Cys (Y918C)]. E365del is the first CMT2S mouse model to be discovered and Y918C is the first human CMT2S allele knock-in model. Phenotypic characterization of the homozygous models found progressive peripheral motor and sensory axonal degeneration. Neuromuscular and locomotor assays indicate that both E365del and Y918C mice have motor deficits, while neurobehavioral characterization of sensory function found that E365del mutants have mechanical allodynia. Analysis of femoral motor and sensory nerves identified axonal degeneration, which does not impact nerve conduction velocities in E365del mice, but it does so in the Y918C model. Based on these results, the E365del mutant mouse, and the human allele knock-in, Y918C, represent mouse models with the hallmark phenotypes of CMT2S, which will be critical for understanding the pathogenic mechanisms of IGHMBP2. These mice will complement existing Ighmbp2 alleles modeling SMARD1 to help understand the complex phenotypic and genotypic heterogeneity that is observed in patients with IGHMBP2 variants.


Subject(s)
Charcot-Marie-Tooth Disease , DNA-Binding Proteins , Disease Models, Animal , Transcription Factors , Animals , Humans , Mice , Charcot-Marie-Tooth Disease/genetics , Charcot-Marie-Tooth Disease/pathology , DNA-Binding Proteins/genetics , Gene Knock-In Techniques , Mice, Inbred C57BL , Muscle Weakness/pathology , Muscular Atrophy/pathology , Phenotype , Transcription Factors/genetics
3.
J Clin Invest ; 131(11)2021 06 01.
Article in English | MEDLINE | ID: mdl-33878035

ABSTRACT

Charcot-Marie-Tooth disease type 4J (CMT4J) is caused by recessive, loss-of-function mutations in FIG4, encoding a phosphoinositol(3,5)P2-phosphatase. CMT4J patients have both neuron loss and demyelination in the peripheral nervous system, with vacuolization indicative of endosome/lysosome trafficking defects. Although the disease is highly variable, the onset is often in childhood and FIG4 mutations can dramatically shorten life span. There is currently no treatment for CMT4J. Here, we present the results of preclinical studies testing a gene-therapy approach to restoring FIG4 expression. A mouse model of CMT4J, the Fig4-pale tremor (plt) allele, was dosed with a single-stranded adeno-associated virus serotype 9 (AAV9) to deliver a codon-optimized human FIG4 sequence. Untreated, Fig4plt/plt mice have a median survival of approximately 5 weeks. When treated with the AAV9-FIG4 vector at P1 or P4, mice survived at least 1 year, with largely normal gross motor performance and little sign of neuropathy by neurophysiological or histopathological evaluation. When mice were treated at P7 or P11, life span was still significantly prolonged and peripheral nerve function was improved, but rescue was less complete. No unanticipated adverse effects were observed. Therefore, AAV9-mediated delivery of FIG4 is a well-tolerated and efficacious strategy in a mouse model of CMT4J.


Subject(s)
Charcot-Marie-Tooth Disease/therapy , Dependovirus , Flavoproteins/biosynthesis , Longevity , Phosphoinositide Phosphatases/biosynthesis , Transduction, Genetic , Animals , Charcot-Marie-Tooth Disease/genetics , Charcot-Marie-Tooth Disease/metabolism , Charcot-Marie-Tooth Disease/pathology , Disease Models, Animal , Female , Flavoproteins/genetics , Male , Mice , Mice, Knockout , Phosphoinositide Phosphatases/genetics
4.
Ann Neurol ; 88(2): 297-308, 2020 08.
Article in English | MEDLINE | ID: mdl-32418267

ABSTRACT

OBJECTIVE: Myotonia is caused by involuntary firing of skeletal muscle action potentials and causes debilitating stiffness. Current treatments are insufficiently efficacious and associated with side effects. Myotonia can be triggered by voluntary movement (electrically induced myotonia) or percussion (mechanically induced myotonia). Whether distinct molecular mechanisms underlie these triggers is unknown. Our goal was to identify ion channels involved in mechanically induced myotonia and to evaluate block of the channels involved as a novel approach to therapy. METHODS: We developed a novel system to enable study of mechanically induced myotonia using both genetic and pharmacologic mouse models of myotonia congenita. We extended ex vivo studies of excitability to in vivo studies of muscle stiffness. RESULTS: As previous work suggests activation of transient receptor potential vanilloid 4 (TRPV4) channels by mechanical stimuli in muscle, we examined the role of this cation channel. Mechanically induced myotonia was markedly suppressed in TRPV4-null muscles and in muscles treated with TRPV4 small molecule antagonists. The suppression of mechanically induced myotonia occurred without altering intrinsic muscle excitability, such that myotonia triggered by firing of action potentials (electrically induced myotonia) was unaffected. When injected intraperitoneally, TRPV4 antagonists lessened the severity of myotonia in vivo by approximately 80%. INTERPRETATION: These data demonstrate that there are distinct molecular mechanisms triggering electrically induced and mechanically induced myotonia. Our data indicates that activation of TRPV4 during muscle contraction plays an important role in triggering myotonia in vivo. Elimination of mechanically induced myotonia by TRPV4 inhibition offers a new approach to treating myotonia. ANN NEUROL 2020;88:297-308.


Subject(s)
Isometric Contraction/physiology , Morpholines/pharmacology , Myotonia Congenita/genetics , Myotonia Congenita/metabolism , Pyrroles/pharmacology , TRPV Cation Channels/antagonists & inhibitors , TRPV Cation Channels/deficiency , Animals , Anthracenes/pharmacology , Isometric Contraction/drug effects , Mice , Mice, Knockout , Morpholines/therapeutic use , Muscle, Skeletal/drug effects , Muscle, Skeletal/physiology , Myotonia Congenita/prevention & control , Pyrroles/therapeutic use
5.
Mol Cell Neurosci ; 105: 103484, 2020 06.
Article in English | MEDLINE | ID: mdl-32240725

ABSTRACT

This study investigates changes with respect to increasing protein levels in dystrophic nerves of two mdx mouse models of Duchenne muscular dystrophy (DMD). We propose that these nerve changes result from progressive ongoing damage to neuromuscular junctions (NMJs) due to repeated intrinsic bouts of necrosis in dystrophic muscles. We compared sciatic nerves from classic mdx mice aged 13, 15 and 18 months (M), with D2.mdx mice (on DBA2 background) aged 9 and 13 M, using immunoblotting to quantify levels of 7 proteins. The neuronal proteins S100ß and Tau5 were increased by 13 M in mdx nerves (compared with WT), indicating ongoing myonecrosis in this strain. In striking contrast there was no difference in levels of these neuronal proteins for D2.mdx and D2.WT sciatic nerves at 13 M, indicating reduced myonecrosis over this time in D2.mdx mice compared with mdx. These novel changes in mdx sciatic nerves by 13 M, suggest early denervation or neurodegeneration of dystrophic nerves that is likely irreversible and progressive. This neuronal readout of persistent myonecrosis may provide a useful new long-term biomarker for preclinical studies that aim to reduce myonecrosis, plus such neuronal changes present potential new drug targets to help maintain the function of DMD muscles.


Subject(s)
Muscle, Skeletal/metabolism , Muscular Dystrophy, Duchenne/metabolism , S100 Calcium Binding Protein beta Subunit/metabolism , tau Proteins/metabolism , Animals , Disease Models, Animal , Mice, Inbred mdx , Neuromuscular Junction/metabolism
6.
J Neuromuscul Dis ; 5(4): 407-417, 2018.
Article in English | MEDLINE | ID: mdl-30198876

ABSTRACT

A new line of dystrophic mdx mice on the DBA/2J (D2) background has emerged as a candidate to study the efficacy of therapeutic approaches for Duchenne muscular dystrophy (DMD). These mice harbor genetic polymorphisms that appear to increase the severity of the dystropathology, with disease modifiers that also occur in DMD patients, making them attractive for efficacy studies and drug development. This workshop aimed at collecting and consolidating available data on the pathological features and the natural history of these new D2/mdx mice, for comparison with classic mdx mice and controls, and to identify gaps in information and their potential value. The overall aim is to establish guidance on how to best use the D2/mdx mouse model in preclinical studies.


Subject(s)
Disease Models, Animal , Muscular Dystrophy, Animal , Muscular Dystrophy, Duchenne , Animals , Mice , Mice, Inbred DBA , Mice, Inbred mdx
7.
J Neuromuscul Dis ; 4(2): 115-126, 2017.
Article in English | MEDLINE | ID: mdl-28550268

ABSTRACT

Laminin-α2 related Congenital Muscular Dystrophy (LAMA2-CMD) is a progressive muscle disease caused by partial or complete deficiency of laminin-211, a skeletal muscle extracellular matrix protein. In the last decade, basic science research has queried underlying disease mechanisms in existing LAMA2-CMD murine models and identified possible clinical targets and pharmacological interventions. Experimental rigor in preclinical studies is critical to efficiently and accurately quantify both negative and positive results, degree of efficiency of potential therapeutics and determine whether to move a compound forward for additional preclinical testing. In this review, we compare published available data measured to assess three common parameters in the widely used mouse model DyW, that mimics LAMA2-CMD, we quantify variability and analyse its possible sources. Finally, on the basis of this analysis, we suggest standard set of assessments and the use of available standardized protocols, to reduce variability of outcomes in the future and to improve the value of preclinical research.


Subject(s)
Disease Models, Animal , Laminin/deficiency , Muscular Dystrophies/diagnosis , Animals , Laminin/genetics , Mice , Muscular Dystrophies/metabolism , Muscular Dystrophies/therapy , Phenotype , Reproducibility of Results
8.
Hum Mol Genet ; 25(1): 130-45, 2016 Jan 01.
Article in English | MEDLINE | ID: mdl-26566673

ABSTRACT

Genetic background significantly affects phenotype in multiple mouse models of human diseases, including muscular dystrophy. This phenotypic variability is partly attributed to genetic modifiers that regulate the disease process. Studies have demonstrated that introduction of the γ-sarcoglycan-null allele onto the DBA/2J background confers a more severe muscular dystrophy phenotype than the original strain, demonstrating the presence of genetic modifier loci in the DBA/2J background. To characterize the phenotype of dystrophin deficiency on the DBA/2J background, we created and phenotyped DBA/2J-congenic Dmdmdx mice (D2-mdx) and compared them with the original, C57BL/10ScSn-Dmdmdx (B10-mdx) model. These strains were compared with their respective control strains at multiple time points between 6 and 52 weeks of age. Skeletal and cardiac muscle function, inflammation, regeneration, histology and biochemistry were characterized. We found that D2-mdx mice showed significantly reduced skeletal muscle function as early as 7 weeks and reduced cardiac function by 28 weeks, suggesting that the disease phenotype is more severe than in B10-mdx mice. In addition, D2-mdx mice showed fewer central myonuclei and increased calcifications in the skeletal muscle, heart and diaphragm at 7 weeks, suggesting that their pathology is different from the B10-mdx mice. The new D2-mdx model with an earlier onset and more pronounced dystrophy phenotype may be useful for evaluating therapies that target cardiac and skeletal muscle function in dystrophin-deficient mice. Our data align the D2-mdx with Duchenne muscular dystrophy patients with the LTBP4 genetic modifier, making it one of the few instances of cross-species genetic modifiers of monogenic traits.


Subject(s)
Disease Models, Animal , Genetic Background , Muscular Dystrophy, Animal/genetics , Animals , Body Weight , Dystrophin/genetics , Echocardiography , Female , Hand Strength , Heart Function Tests , Male , Mice , Mice, Inbred C57BL , Mice, Inbred DBA , Mice, Inbred mdx , Muscle Contraction , Muscles/pathology , Muscular Dystrophy, Animal/pathology , Myofibrils/pathology , Myositis/genetics , Myositis/pathology , Organ Size , Phenotype
9.
Neuron ; 88(5): 892-901, 2015 Dec 02.
Article in English | MEDLINE | ID: mdl-26637796

ABSTRACT

Noncoding expansions of a hexanucleotide repeat (GGGGCC) in the C9orf72 gene are the most common cause of familial amyotrophic lateral sclerosis and frontotemporal dementia. Here we report transgenic mice carrying a bacterial artificial chromosome (BAC) containing the full human C9orf72 gene with either a normal allele (15 repeats) or disease-associated expansion (∼100-1,000 repeats; C9-BACexp). C9-BACexp mice displayed pathologic features seen in C9orf72 expansion patients, including widespread RNA foci and repeat-associated non-ATG (RAN) translated dipeptides, which were suppressed by antisense oligonucleotides targeting human C9orf72. Nucleolin distribution was altered, supporting that either C9orf72 transcripts or RAN dipeptides promote nucleolar dysfunction. Despite early and widespread production of RNA foci and RAN dipeptides in C9-BACexp mice, behavioral abnormalities and neurodegeneration were not observed even at advanced ages, supporting the hypothesis that RNA foci and RAN dipeptides occur presymptomatically and are not sufficient to drive neurodegeneration in mice at levels seen in patients.


Subject(s)
Amyotrophic Lateral Sclerosis/pathology , Brain/pathology , DNA Repeat Expansion/genetics , Frontotemporal Dementia/pathology , Proteins/genetics , Spinal Cord/pathology , Age Factors , Amyotrophic Lateral Sclerosis/genetics , Amyotrophic Lateral Sclerosis/physiopathology , Animals , Brain/metabolism , C9orf72 Protein , Cells, Cultured , Chromosomes, Artificial, Bacterial/genetics , Chromosomes, Artificial, Bacterial/metabolism , Disease Models, Animal , Frontotemporal Dementia/genetics , Frontotemporal Dementia/physiopathology , Glutamic Acid/pharmacology , Humans , Mice , Mice, Transgenic , Motor Activity/genetics , Muscle Strength/genetics , Neuromuscular Junction/genetics , Neuromuscular Junction/pathology , Neurons/drug effects , Psychomotor Performance/physiology , Spinal Cord/metabolism
10.
Proc Natl Acad Sci U S A ; 112(43): E5863-72, 2015 Oct 27.
Article in English | MEDLINE | ID: mdl-26460027

ABSTRACT

Clinical presentation of spinal muscular atrophy (SMA) ranges from a neonatal-onset, very severe disease to an adult-onset, milder form. SMA is caused by the mutation of the Survival Motor Neuron 1 (SMN1) gene, and prognosis inversely correlates with the number of copies of the SMN2 gene, a human-specific homolog of SMN1. Despite progress in identifying potential therapies for the treatment of SMA, many questions remain including how late after onset treatments can still be effective and what the target tissues should be. These questions can be addressed in part with preclinical animal models; however, modeling the array of SMA severities in the mouse, which lacks SMN2, has proven challenging. We created a new mouse model for the intermediate forms of SMA presenting with a delay in neuromuscular junction maturation and a decrease in the number of functional motor units, all relevant to the clinical presentation of the disease. Using this new model, in combination with clinical electrophysiology methods, we found that administering systemically SMN-restoring antisense oligonucleotides (ASOs) at the age of onset can extend survival and rescue the neurological phenotypes. Furthermore, these effects were also achieved by administration of the ASOs late after onset, independent of the restoration of SMN in the spinal cord. Thus, by adding to the limited repertoire of existing mouse models for type II/III SMA, we demonstrate that ASO therapy can be effective even when administered after onset of the neurological symptoms, in young adult mice, and without being delivered into the central nervous system.


Subject(s)
Muscular Atrophy, Spinal/physiopathology , Oligonucleotides, Antisense/pharmacology , Animals , Disease Models, Animal , Mice , Phenotype
11.
Genome Res ; 25(7): 948-57, 2015 Jul.
Article in English | MEDLINE | ID: mdl-25917818

ABSTRACT

Spontaneously arising mouse mutations have served as the foundation for understanding gene function for more than 100 years. We have used exome sequencing in an effort to identify the causative mutations for 172 distinct, spontaneously arising mouse models of Mendelian disorders, including a broad range of clinically relevant phenotypes. To analyze the resulting data, we developed an analytics pipeline that is optimized for mouse exome data and a variation database that allows for reproducible, user-defined data mining as well as nomination of mutation candidates through knowledge-based integration of sample and variant data. Using these new tools, putative pathogenic mutations were identified for 91 (53%) of the strains in our study. Despite the increased power offered by potentially unlimited pedigrees and controlled breeding, about half of our exome cases remained unsolved. Using a combination of manual analyses of exome alignments and whole-genome sequencing, we provide evidence that a large fraction of unsolved exome cases have underlying structural mutations. This result directly informs efforts to investigate the similar proportion of apparently Mendelian human phenotypes that are recalcitrant to exome sequencing.


Subject(s)
Exome , Mutation , Animals , Female , Genetic Diseases, Inborn/genetics , Genetic Linkage , Genetic Variation , Genome-Wide Association Study , Genomics/methods , High-Throughput Nucleotide Sequencing , Male , Mice , Phenotype , Reproducibility of Results
12.
Brain Res ; 1584: 59-72, 2014 Oct 10.
Article in English | MEDLINE | ID: mdl-24141148

ABSTRACT

ALS therapy development has been hindered by the lack of rodent animal models. The discovery of TDP-43, a transcription factor that accumulates in the cytoplasm of motor neurons (MNs) in most cases of ALS, prompted attempts to develop TDP-43-based models of the disease. The current study sought to examine, in extensive detail, the emerging disease phenotype of a transgenic mouse model that overexpresses a mutant human TDP-43 (hTDP-43) gene under mouse prion promoter control. Careful attention was given to ALS-like characteristics to determine the appropriateness of this model for testing therapies for ALS. In light of previous reports that gastrointestinal (GI) dysfunction is responsible for early death in these mice, gut immunohistochemistry (IHC) and longitudinal gut motility assays were used to identify the onset and the progression of these defects. IHC studies revealed that site-specific overexpression of the hTDP-43 transgene in colonic myenteric plexes resulted in progressive neurodegeneration in this region. This change was associated with progressively reduced GI motility, culminating in frank stasis that was primarily responsible for decreasing longevity in these mice. The disease phenotype was gender- and genetic background-dependent, with congenic C57BL/6J male mice exhibiting the most aggressive form of the disease. Spinal cord IHC revealed ubiquitin-positive inclusions, but not TDP-43 aggregates, in the cytoplasm of MNs. Neither gender exhibited compelling ALS-like neuromuscular deficits, irrespective of age. While this model may be useful for studying GI tract neurodegeneration, in its present state it does not display a phenotype suitable for testing ALS therapeutics.


Subject(s)
Amyotrophic Lateral Sclerosis/metabolism , Amyotrophic Lateral Sclerosis/pathology , Colon/pathology , DNA-Binding Proteins/metabolism , Myenteric Plexus/pathology , Animals , Colon/innervation , Colon/metabolism , DNA-Binding Proteins/genetics , Female , Gastrointestinal Motility , Gastrointestinal Tract/pathology , Glial Fibrillary Acidic Protein , Humans , Inclusion Bodies/metabolism , Inclusion Bodies/pathology , Male , Mice , Mice, Congenic , Mice, Inbred C57BL , Mice, Transgenic , Motor Neurons/metabolism , Motor Neurons/pathology , Myenteric Plexus/metabolism , Nerve Tissue Proteins/metabolism , Sex Factors , Spinal Cord/metabolism , Spinal Cord/pathology , Ubiquitin/metabolism
13.
Dis Model Mech ; 6(3): 780-92, 2013 May.
Article in English | MEDLINE | ID: mdl-23519028

ABSTRACT

Charcot-Marie-Tooth disease (CMT) is a clinically and genetically heterogeneous condition characterized by peripheral axon degeneration with subsequent motor and sensory deficits. Several CMT gene products function in endosomal sorting and trafficking to the lysosome, suggesting that defects in this cellular pathway might present a common pathogenic mechanism for these conditions. LRSAM1 is an E3 ubiquitin ligase that is implicated in this process, and mutations in LRSAM1 have recently been shown to cause CMT. We have generated mouse mutations in Lrsam1 to create an animal model of this form of CMT (CMT2P). Mouse Lrsam1 is abundantly expressed in the motor and sensory neurons of the peripheral nervous system. Both homozygous and heterozygous mice have largely normal neuromuscular performance and only a very mild neuropathy phenotype with age. However, Lrsam1 mutant mice are more sensitive to challenge with acrylamide, a neurotoxic agent that causes axon degeneration, indicating that the axons in the mutant mice are indeed compromised. In transfected cells, LRSAM1 primarily localizes in a perinuclear compartment immediately beyond the Golgi and shows little colocalization with components of the endosome to lysosome trafficking pathway, suggesting that other cellular mechanisms also merit consideration.


Subject(s)
Axons/metabolism , Charcot-Marie-Tooth Disease/enzymology , Nerve Degeneration/pathology , Peripheral Nervous System/pathology , Ubiquitin-Protein Ligases/metabolism , Acrylamide/pharmacology , Animals , Axons/drug effects , Behavior, Animal/drug effects , Cell Line , Charcot-Marie-Tooth Disease/complications , Charcot-Marie-Tooth Disease/pathology , Disease Models, Animal , Endosomes/drug effects , Endosomes/metabolism , Humans , Lysosomes/drug effects , Lysosomes/metabolism , Mice , Mice, Mutant Strains , Mutagenesis/genetics , Mutation/genetics , Nerve Degeneration/complications , Nerve Degeneration/enzymology , Neuromuscular Junction/drug effects , Neuromuscular Junction/metabolism , Neuromuscular Junction/pathology , Peripheral Nervous System/drug effects , Peripheral Nervous System/enzymology , Phenotype , Protein Transport/drug effects , Subcellular Fractions/drug effects , Subcellular Fractions/enzymology , Transfection
14.
Hum Mol Genet ; 21(20): 4431-47, 2012 Oct 15.
Article in English | MEDLINE | ID: mdl-22802075

ABSTRACT

A number of mouse models for spinal muscular atrophy (SMA) have been genetically engineered to recapitulate the severity of human SMA by using a targeted null mutation at the mouse Smn1 locus coupled with the transgenic addition of varying copy numbers of human SMN2 genes. Although this approach has been useful in modeling severe SMA and very mild SMA, a mouse model of the intermediate form of the disease would provide an additional research tool amenable for drug discovery. In addition, many of the previously engineered SMA strains are multi-allelic by design, containing a combination of transgenes and targeted mutations in the homozygous state, making further genetic manipulation difficult. A new genetic engineering approach was developed whereby variable numbers of SMN2 sequences were incorporated directly into the murine Smn1 locus. Using combinations of these alleles, we generated an allelic series of SMA mouse strains harboring no, one, two, three, four, five, six or eight copies of SMN2. We report here the characterization of SMA mutants in this series that displayed a range in disease severity from embryonic lethal to viable with mild neuromuscular deficits.


Subject(s)
Muscular Atrophy, Spinal/genetics , Neuromuscular Junction/genetics , Alleles , Animals , Behavior, Animal , Disease Models, Animal , Genotype , Humans , Mice , Mice, Inbred Strains , Neuromuscular Junction/metabolism , Phenotype , Survival of Motor Neuron 1 Protein/genetics , Survival of Motor Neuron 1 Protein/metabolism , Survival of Motor Neuron 2 Protein/genetics , Survival of Motor Neuron 2 Protein/metabolism
15.
PLoS One ; 7(1): e30217, 2012.
Article in English | MEDLINE | ID: mdl-22272310

ABSTRACT

Glycine is the major inhibitory neurotransmitter in the spinal cord and some brain regions. The presynaptic glycine transporter, GlyT2, is required for sustained glycinergic transmission through presynaptic reuptake and recycling of glycine. Mutations in SLC6A5, encoding GlyT2, cause hereditary hyperekplexia in humans, and similar phenotypes in knock-out mice, and variants are associated with schizophrenia. We identified a spontaneous mutation in mouse Slc6a5, caused by a MusD retrotransposon insertion. The GlyT2 protein is undetectable in homozygous mutants, indicating a null allele. Homozygous mutant mice are normal at birth, but develop handling-induced spasms at five days of age, and only survive for two weeks, but allow the study of early activity-regulated developmental processes. At the neuromuscular junction, synapse elimination and the switch from embryonic to adult acetylcholine receptor subunits are hastened, consistent with a presumed increase in motor neuron activity, and transcription of acetylcholine receptors is elevated. Heterozygous mice, which show no reduction in lifespan but nonetheless have reduced levels of GlyT2, have a normal thermal sensitivity with the hot-plate test, but differences in repetitive grooming and decreased sleep time with home-cage monitoring. Open-field and elevated plus-maze tests did not detect anxiety-like behaviors; however, the latter showed a hyperactivity phenotype. Importantly, grooming and hyperactivity are observed in mouse schizophrenia models. Thus, mutations in Slc6a5 show changes in neuromuscular junction development as homozygotes, and behavioral phenotypes as heterozygotes, indicating their usefulness for studies related to glycinergic dysfunction.


Subject(s)
Glycine Plasma Membrane Transport Proteins/genetics , Mutagenesis, Insertional , Neuromuscular Junction/physiology , Psychomotor Performance/physiology , Retroelements/genetics , Animals , Anxiety , Blotting, Western , Chromosome Mapping , Chromosomes, Mammalian/genetics , Female , Genetic Association Studies , Glycine Plasma Membrane Transport Proteins/metabolism , Grooming , Humans , Male , Maze Learning , Mice , Mice, Inbred DBA , Mice, Inbred NOD , Mice, Knockout , Mice, SCID , Motor Activity , Mutation , Neural Inhibition/genetics , Neural Inhibition/physiology , Neuromuscular Junction/genetics , Spinal Cord/metabolism , Spinal Cord/physiopathology
16.
Hum Mol Genet ; 20(23): 4617-33, 2011 Dec 01.
Article in English | MEDLINE | ID: mdl-21890498

ABSTRACT

Congenital myasthenic syndromes (CMS) are inherited diseases affecting the neuromuscular junction (NMJ). Mutations in AGRIN (AGRN) and other genes in the AGRIN signaling pathway cause CMS, and gene targeting studies in mice confirm the importance of this pathway for NMJ formation. However, these mouse mutations are complete loss-of-function alleles that result in an embryonic failure of NMJ formation, and homozygous mice do not survive postpartum. Therefore, mouse models of AGRIN-related CMS that would allow preclinical testing or studies of postnatal disease progression are lacking. Using chemical mutagenesis in mice, we identified a point mutation in Agrn that results in a partial loss-of-function allele, creating a valid model of CMS. The mutation changes phenylalanine 1061 to serine in the SEA domain of AGRIN, a poorly characterized motif shared by other extracellular proteoglycans. NMJs in homozygous mice progressively degrade postnataly. Severity differs with genetic background, in different muscles, and in different regions within a muscle in a pattern matching mouse models of motor neuron disease. Mutant NMJs have decreased acetylcholine receptor density and an increased subsynaptic reticulum, evident by electron microscopy. Synapses eventually denervate and the muscles atrophy. Molecularly, several factors contribute to the partial loss of AGRIN's function. The mutant protein is found at NMJs, but is processed differently than wild-type, with decreased glycosylation, changes in sensitivity to the protease neurotrypsin and other proteolysis, and less efficient externalization and secretion. Therefore, the Agrn point mutation is a model for CMS caused by Agrn mutations and potentially other related neuromuscular diseases.


Subject(s)
Agrin/genetics , Disease Models, Animal , Genetic Predisposition to Disease , Myasthenic Syndromes, Congenital/genetics , Agrin/chemistry , Agrin/metabolism , Alleles , Amino Acid Sequence , Animals , Animals, Newborn , Base Sequence , Cell Membrane/metabolism , Glycosylation , Mice , Mitochondria/metabolism , Mitochondria/pathology , Mitochondria/ultrastructure , Molecular Sequence Data , Motor Neuron Disease/genetics , Motor Neuron Disease/pathology , Muscle Fibers, Skeletal/metabolism , Muscle Fibers, Skeletal/pathology , Muscle Fibers, Skeletal/ultrastructure , Mutant Proteins/metabolism , Mutation/genetics , Myasthenic Syndromes, Congenital/pathology , Neuromuscular Junction/metabolism , Neuromuscular Junction/pathology , Neuromuscular Junction/ultrastructure , Phenotype , Protein Stability , Protein Transport , Proteolysis , Reproducibility of Results
17.
PLoS One ; 3(4): e2084, 2008 Apr 30.
Article in English | MEDLINE | ID: mdl-18446215

ABSTRACT

BACKGROUND: The Dystrophin-glycoprotein complex (DGC) comprises dystrophin, dystroglycan, sarcoglycan, dystrobrevin and syntrophin subunits. In muscle fibers, it is thought to provide an essential mechanical link between the intracellular cytoskeleton and the extracellular matrix and to protect the sarcolemma during muscle contraction. Mutations affecting the DGC cause muscular dystrophies. Most members of the DGC are also concentrated at the neuromuscular junction (NMJ), where their deficiency is often associated with NMJ structural defects. Hence, synaptic dysfunction may also intervene in the pathology of dystrophic muscles. Dystroglycan is a central component of the DGC because it establishes a link between the extracellular matrix and Dystrophin. In this study, we focused on the synaptic role of Dystroglycan (Dg) in Drosophila. METHODOLOGY/PRINCIPAL FINDINGS: We show that Dg was concentrated postsynaptically at the glutamatergic NMJ, where, like in vertebrates, it controls the concentration of synaptic Laminin and Dystrophin homologues. We also found that synaptic Dg controlled the amount of postsynaptic 4.1 protein Coracle and alpha-Spectrin, as well as the relative subunit composition of glutamate receptors. In addition, both Dystrophin and Coracle were required for normal Dg concentration at the synapse. In electrophysiological recordings, loss of postsynaptic Dg did not affect postsynaptic response, but, surprisingly, led to a decrease in glutamate release from the presynaptic site. CONCLUSION/SIGNIFICANCE: Altogether, our study illustrates a conservation of DGC composition and interactions between Drosophila and vertebrates at the synapse, highlights new proteins associated with this complex and suggests an unsuspected trans-synaptic function of Dg.


Subject(s)
Drosophila melanogaster/metabolism , Dystroglycans/metabolism , Muscle, Skeletal/metabolism , Neuromuscular Junction/metabolism , Neurotransmitter Agents/metabolism , Presynaptic Terminals/metabolism , Animals , Cytoskeleton/metabolism , Drosophila Proteins/metabolism , Drosophila melanogaster/cytology , Dystrophin/metabolism , Intracellular Space/metabolism , Laminin/metabolism , Membrane Proteins/metabolism , Neuromuscular Junction/cytology , Protein Subunits/metabolism , Protein Transport , Receptors, Glutamate/metabolism , Spectrin/metabolism
18.
Eur J Neurosci ; 24(1): 37-44, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16882006

ABSTRACT

Barh1/h2 genes encode two related homeobox transcription factors (B-H1 and B-H2) previously shown to play essential roles in the formation and specification of the distal leg segments and in retinal neurogenesis. Here we describe the restricted expression pattern of the B-H1/-H2 homeoprotein within the embryonic ventral nerve cord of Drosophila. We show that B-H1/-H2 are specifically expressed in a subset of dopaminergic neurons, namely the unpaired ventral midline dopaminergic neuron, and in a subpopulation of laterally projecting motoneurons, i.e. the five motoneurons forming the segmental nerve a (SNa) branch. Using the GAL4-UAS system we show that B-H1/-H2(Gal4) in combination with a membrane-targeted enhanced green fluorescent protein reporter line provides a powerful genetic tool reproducibly to label SNa motoneuron projections and terminals at the periphery, and their dendritic tree in the ventral nerve cord. Thus, the highly restricted expression pattern of the B-H1/-H2 homeoproteins and notably the related Gal4 driver represent powerful genetic tools to identify and study genes that control axon guidance, synaptogenesis or dendritic arborization within a small subpopulation of motoneurons identifiable from embryogenesis to late larval stages.


Subject(s)
Dopamine/metabolism , Drosophila Proteins/biosynthesis , Drosophila/metabolism , Eye Proteins/biosynthesis , Motor Neurons/metabolism , Transcription Factors/biosynthesis , Animals , Axons/metabolism , Central Nervous System/embryology , Central Nervous System/growth & development , Central Nervous System/metabolism , Drosophila/embryology , Drosophila/growth & development , Drosophila Proteins/genetics , Embryo, Nonmammalian/metabolism , Eye Proteins/genetics , Homeodomain Proteins , Immunohistochemistry , Larva/metabolism , Transcription Factors/genetics
19.
J Neurosci ; 24(41): 9105-16, 2004 Oct 13.
Article in English | MEDLINE | ID: mdl-15483129

ABSTRACT

In vertebrates, several groups of metabotropic glutamate receptors (mGluRs) are known to modulate synaptic properties. In contrast, the Drosophila genome encodes a single functional mGluR (DmGluRA), an ortholog of vertebrate group II mGluRs, greatly expediting the functional characterization of mGluR-mediated signaling in the nervous system. We show here that DmGluRA is expressed at the glutamatergic neuromuscular junction (NMJ), localized in periactive zones of presynaptic boutons but excluded from active sites. Null DmGluRA mutants are completely viable, and all of the basal NMJ synaptic transmission properties are normal. In contrast, DmGluRA mutants display approximately a threefold increase in synaptic facilitation during short stimulus trains. Prolonged stimulus trains result in very strongly increased ( approximately 10-fold) augmentation, including the appearance of asynchronous, bursting excitatory currents never observed in wild type. Both defects are rescued by expression of DmGluRA only in the neurons, indicating a specific presynaptic requirement. These phenotypes are reminiscent of hyperexcitable mutants, suggesting a role of DmGluRA signaling in the regulation of presynaptic excitability properties. The mutant phenotypes could not be replicated by acute application of mGluR antagonists, suggesting that DmGluRA regulates the development of presynaptic properties rather than directly controlling short-term modulation. DmGluRA mutants also display mild defects in NMJ architecture: a decreased number of synaptic boutons accompanied by an increase in mean bouton size. These morphological changes bidirectionally correlate with DmGluRA levels in the presynaptic terminal. These data reveal the following two roles for DmGluRA in presynaptic mechanisms: (1) modulation of presynaptic excitability properties important for the control of activity-dependent neurotransmitter release and (2) modulation of synaptic architecture.


Subject(s)
Drosophila Proteins/metabolism , Receptors, Metabotropic Glutamate/metabolism , Receptors, Metabotropic Glutamate/physiology , Synapses/physiology , Action Potentials/physiology , Animals , Animals, Genetically Modified , Drosophila Proteins/genetics , Drosophila melanogaster , Electric Stimulation , Feedback, Physiological/physiology , GTP-Binding Protein beta Subunits/metabolism , Glutamic Acid/metabolism , Larva , Mutation , Neuromuscular Junction/metabolism , Neuromuscular Junction/physiology , Neuromuscular Junction/ultrastructure , Neuronal Plasticity/genetics , Neuronal Plasticity/physiology , Patch-Clamp Techniques , Presynaptic Terminals/metabolism , Presynaptic Terminals/ultrastructure , Receptors, Metabotropic Glutamate/genetics , Synapses/metabolism , Synapses/ultrastructure , Synaptic Transmission/physiology
20.
J Neurosci ; 24(29): 6573-7, 2004 Jul 21.
Article in English | MEDLINE | ID: mdl-15269269

ABSTRACT

A protein-trap screen using the Drosophila neuromuscular junction (NMJ) as a model synapse was performed to identify genes that control synaptic structure or plasticity. We found that Shaggy (Sgg), the Drosophila homolog of the mammalian glycogen synthase kinases 3 alpha and beta, two serine-threonine kinases, was concentrated at this synapse. Using various combinations of mutant alleles of shaggy, we found that Shaggy negatively controlled the NMJ growth. Moreover, tissue-specific expression of a dominant-negative Sgg indicated that this kinase is required in the motoneuron, but not in the muscle, to control NMJ growth. Finally, we show that Sgg controlled the microtubule cytoskeleton dynamics in the motoneuron and that Futsch, a microtubule-associated protein, was required for Shaggy function on synaptic growth.


Subject(s)
Drosophila Proteins/physiology , Drosophila melanogaster/enzymology , Drosophila melanogaster/growth & development , Glycogen Synthase Kinase 3/physiology , Neuromuscular Junction/enzymology , Neuromuscular Junction/growth & development , Animals , Drosophila Proteins/analysis , Drosophila Proteins/genetics , Drosophila melanogaster/ultrastructure , Glycogen Synthase Kinase 3/analysis , Glycogen Synthase Kinase 3/genetics , Larva/enzymology , Microtubule-Associated Proteins/genetics , Microtubules/ultrastructure , Motor Neurons/enzymology , Mutation , Nerve Growth Factors/genetics , Neuronal Plasticity , Presynaptic Terminals/enzymology , Presynaptic Terminals/ultrastructure
SELECTION OF CITATIONS
SEARCH DETAIL
...